Ana Lisa Basquiera

Prof. Dr. Ana Lisa Basquiera

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Blood
Verified
Journal Article
Open access
DKDavid John Kuter
David John Kuter
WGWaleed Ghanima
Waleed Ghanima
NCNichola Cooper
Nichola Cooper
HLHoward A. Liebman
Howard A. Liebman
LZLei Zhang
Lei Zhang
ADAhmed Daak
Ahmed Daak
Rilzabrutinib is a covalent, reversible Bruton tyrosine kinase inhibitor targeting multiple immune thrombocytopenia (ITP)-related mechanisms. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg twice daily (n = 133) vs placebo (n = 69) for 24 weeks. At baseline overall, median age was 47 years, 63% female, 7.7 year median ITP duration, and 28% prior splenectomy. Overall (N = 202), 85 (64%) rilzabrutinib and 22 (32%) placebo patients achieved platelet response (≥50 × 109/L or 30 × 109/L to <50 × 109/L and doubled from baseline) during the first 12 weeks and were eligible to continue. The primary end point, durable platelet response (platelet count ≥50 × 109/L for ≥two-thirds of ≥8 of the last 12 of 24 weeks without rescue therapy), was observed in 31 (23%) rilzabrutinib vs 0 placebo patients (P < .0001). All secondary efficacy end points were significantly superior for rilzabrutinib (P < .05). Median time to first platelet response was 15 days in rilzabrutinib responders. Rilzabrutinib significantly reduced rescue therapy use by 52% (P = .0007) and improved week 25 bleeding scores (P = .0006). Improved physical fatigue was sustained from week 13 (P = .01) through 25 (P = .0003). Treatment-related adverse events were mainly grade 1/2. One rilzabrutinib patient with multiple risk factors had serious treatment-related grade 3 peripheral embolism (lower left leg), and another died from unrelated pneumonia. Rilzabrutinib in patients who failed multiple previous ITP therapies showed rapid and durable platelet response, reduced rescue medication and bleeding, improved physical fatigue, and favorable safety. Trial registration: www.clinicaltrials.gov (#NCT04562766) and www.clinicaltrialsregister.eu (#2020-002063-60).

28 March 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
CCCinthya Correa
Cinthya Correa
OGOscar Gonzalez-Ramella
Oscar Gonzalez-Ramella
HBHelen Baldomero
Helen Baldomero
ABAna Lisa Basquiera
Ana Lisa Basquiera
RBRosio Baena
Rosio Baena
SGSebastian Galeano
Sebastian Galeano

21 August 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
OÓOn Behalf Of Gatmo (Grupo Argentino de Trasplante de Médula Ósea)
On Behalf Of Gatmo (Grupo Argentino de Trasplante de Médula Ósea)
MRMaría Marta Rivas
María Marta Rivas
MBMariano Berro
Mariano Berro
MPMaría Virginia Prates
María Virginia Prates
SYSebastián Yantorno
Sebastián Yantorno
GKGustavo Kusminsky
Gustavo Kusminsky

1 May 2023 in JCO Global Oncology
Verified
Journal Article
Open access
ABAna Lisa Basquiera
Ana Lisa Basquiera
MSMaria Cristina Seiwald
Maria Cristina Seiwald
CACarlos Roberto Best Aguilera
Carlos Roberto Best Aguilera
LELeonardo Enciso
Leonardo Enciso
IFIsolda Fernandez
Isolda Fernandez
VRVanderson Rocha
Vanderson Rocha
PURPOSE: Despite strong induction chemotherapy response rates, only 30%-40% of patients with adult B-cell acute lymphoblastic leukemia (ALL) attain long-term remission. This study analyzes ALL in Latin America (LA) and recommends diagnosis, treatment, and management protocols.METHODS: The Americas Health Foundation organized a panel of hematologists from Argentina, Brazil, Chile, Colombia, and Mexico to examine ALL diagnosis and therapy and produce recommendations.RESULTS: Lack of regional data, unequal access to diagnosis and therapy, inadequate treatment response, and uneven health care distribution complicate adult ALL management. The panel recommended diagnosis, first-line and refractory treatment, and post-transplantation maintenance. Targeted treatments, including rituximab, blinatumomab, and inotuzumab ozogamicin, are becoming available in LA and must be equitably accessed.CONCLUSION: This review adapts global information on treating ALL to LA. Governments, the medical community, society, academia, industry, and patient advocates must work together to improve policies.

18 April 2025 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
SGSebastian Galeano
Sebastian Galeano
CBCarmem Bonfim
Carmem Bonfim
AKAmado Karduss
Amado Karduss
GJGregorio Jaimovich
Gregorio Jaimovich
ALAndrés Gómez-De León
Andrés Gómez-De León
CFCristóbal Frutos
Cristóbal Frutos
A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.

24 September 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
O(On Behalf Of Grupo Argentino de Trasplante de Médula Ósea (Gatmo)
On Behalf Of Grupo Argentino de Trasplante de Médula Ósea (Gatmo)
ABAna Lisa Basquiera
Ana Lisa Basquiera
MBMariano Berro
Mariano Berro
SYSebastián Yantorno
Sebastián Yantorno
MCMartín Castro
Martín Castro
JAJorge A. Arbelbide
Jorge A. Arbelbide